Total Payments
$103,049
2024 Payments
$10,964
Companies
52
Transactions
339
Medicare Patients
4,845
Medicare Billing
$633,027
Payment Breakdown by Category
Research$51,149 (49.6%)
Consulting$39,649 (38.5%)
Food & Beverage$5,950 (5.8%)
Other$3,795 (3.7%)
Travel$1,913 (1.9%)
Education$593.86 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $51,149 | 17 | 49.6% |
| Consulting Fee | $39,649 | 29 | 38.5% |
| Food and Beverage | $5,950 | 269 | 5.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,795 | 1 | 3.7% |
| Travel and Lodging | $1,913 | 11 | 1.9% |
| Education | $593.86 | 12 | 0.6% |
Payments by Type
General
$51,900
322 transactions
Research
$51,149
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $25,571 | 5 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $19,215 | 10 | $0 (2022) |
| Genentech USA, Inc. | $14,847 | 23 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $6,799 | 19 | $0 (2022) |
| F. Hoffmann-La Roche AG | $6,363 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $5,380 | 42 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,819 | 11 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $3,795 | 1 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $2,831 | 8 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $2,800 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,964 | 69 | F. Hoffmann-La Roche AG ($6,363) |
| 2023 | $38,089 | 58 | Eli Lilly and Company ($24,071) |
| 2022 | $20,319 | 70 | Regeneron Pharmaceuticals, Inc. ($6,799) |
| 2021 | $28,897 | 70 | Rigel Pharmaceuticals, Inc. ($18,596) |
| 2020 | $3,903 | 23 | Agios Pharmaceuticals, Inc. ($2,800) |
| 2019 | $671.75 | 44 | Janssen Biotech, Inc. ($160.02) |
| 2018 | $204.23 | 5 | Janssen Scientific Affairs, LLC ($105.03) |
All Payment Transactions
339 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,181.45 | Research |
| Study: MorningSun | ||||||
| 12/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $9.86 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $8.49 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: PAIN | ||||||
| 11/21/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $35.33 | General |
| Category: Oncology | ||||||
| 11/15/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $6.28 | General |
| Category: Oncology | ||||||
| 10/23/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $90.51 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $22.36 | General |
| 10/02/2024 | HISTOSONICS,INC. | — | Food and Beverage | Cash or cash equivalent | $148.96 | General |
| 10/02/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $3.69 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Oncology | ||||||
| 09/10/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Oncology | ||||||
| 08/22/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.02 | General |
| Category: Hematology/Oncology | ||||||
| 07/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $21,499 | 2 |
| C-935788-057 | Rigel Pharmaceuticals, Inc. | $18,596 | 9 |
| MorningSun | F. Hoffmann-La Roche AG | $6,363 | 2 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | Eli Lilly and Company | $1,595 | 1 |
| A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $1,500 | 1 |
| STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) | Eli Lilly and Company | $977.60 | 1 |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Rigel Pharmaceuticals, Inc. | $619.14 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,173 | 30,225 | $560,231 | $174,216 |
| 2022 | 33 | 1,252 | 24,233 | $498,874 | $149,771 |
| 2021 | 35 | 1,277 | 22,131 | $456,117 | $177,541 |
| 2020 | 30 | 1,143 | 6,187 | $362,716 | $131,499 |
Total Patients
4,845
Total Services
82,776
Medicare Billing
$633,027
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 168 | 349 | $56,538 | $32,586 | 57.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 229 | $81,295 | $21,873 | 26.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 15 | 17 | $40,800 | $18,661 | 45.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 20 | 21,750 | $87,000 | $18,653 | 21.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,020 | $41,280 | $18,648 | 45.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 18 | 20 | $20,000 | $8,012 | 40.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 111 | $12,765 | $6,949 | 54.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 210 | 700 | $12,600 | $5,848 | 46.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $11,660 | $5,387 | 46.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 38 | $12,540 | $5,214 | 41.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 33 | $7,755 | $4,385 | 56.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 192 | 570 | $23,370 | $4,317 | 18.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 30 | 185 | $16,650 | $3,953 | 23.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 12 | 51 | $3,570 | $3,557 | 99.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 41 | 75 | $12,000 | $3,431 | 28.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 14 | 19 | $10,165 | $3,045 | 30.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 43 | $7,525 | $1,855 | 24.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $3,375 | $1,549 | 45.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 56 | $4,480 | $1,207 | 26.9% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 16 | 21 | $10,500 | $895.16 | 8.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 82 | $3,444 | $864.77 | 25.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 80 | $4,400 | $801.17 | 18.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 13 | $1,352 | $711.09 | 52.6% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 17 | $2,210 | $418.88 | 19.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 14 | 460 | $34,500 | $365.81 | 1.1% |
About Dr. Ayed Ayed, M.D
Dr. Ayed Ayed, M.D is a Hematology & Oncology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/05/2012. The National Provider Identifier (NPI) number assigned to this provider is 1639428782.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ayed Ayed, M.D has received a total of $103,049 in payments from pharmaceutical and medical device companies, with $10,964 received in 2024. These payments were reported across 339 transactions from 52 companies. The most common payment nature is "" ($51,149).
As a Medicare-enrolled provider, Ayed has provided services to 4,845 Medicare beneficiaries, totaling 82,776 services with total Medicare billing of $633,027. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jacksonville, FL
- Active Since 09/05/2012
- Last Updated 07/10/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1639428782
Products in Payments
- Tavalisse (Drug) $19,215
- LIBTAYO (Biological) $8,637
- VENCLEXTA (Biological) $3,990
- Tazverik (Drug) $3,795
- Columvi (Biological) $3,280
- TIBSOVO (Drug) $2,800
- Lunsumio (Biological) $2,775
- TECVAYLI (Biological) $2,348
- clonoSEQ (Device) $2,347
- DARZALEX (Biological) $2,203
- ABECMA (Biological) $1,976
- IMBRUVICA (Drug) $1,814
- CALQUENCE (Drug) $1,730
- POLIVY (Biological) $1,592
- RYBREVANT (Drug) $998.80
- ADCETRIS (Biological) $390.19
- OPDIVO (Biological) $230.90
- ELIQUIS (Drug) $225.62
- XTANDI (Drug) $197.60
- KRAZATI (Drug) $175.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Jacksonville
Arnab Basu, Md, MD
Hematology & Oncology — Payments: $345,058
Hematology & Oncology $345,058
Edith Perez, Md, MD
Hematology & Oncology — Payments: $282,574
Hematology & Oncology $282,574
Saranya Chumsri, Md, MD
Hematology & Oncology — Payments: $259,129
Hematology & Oncology $259,129
Sikander Ailawadhi, Md, MD
Hematology & Oncology — Payments: $244,554
Hematology & Oncology $244,554
James Foran, Md, MD
Hematology & Oncology — Payments: $157,939
Hematology & Oncology $157,939
Dr. Gregory Pennock, Md, MD
Hematology & Oncology — Payments: $133,778
Hematology & Oncology $133,778